Skip to main content
. Author manuscript; available in PMC: 2009 Nov 15.
Published in final edited form as: Cancer Res. 2008 Nov 15;68(22):9375–9383. doi: 10.1158/0008-5472.CAN-08-2223

Figure 3. Consequences of MEK-inhibition in BRAF mutant NSCLC cell lines.

Figure 3

A. Immunoblot of cell cycle related proteins in response to MEK inhibition as a function of time following MEK inhibition (50nM PD0325901). For both the high activity (HCC364) and low activity (H1666) BRAF mutant cell lines, pERK downregulation was accompanied by loss of D-cyclin protein expression, induction of p27 expression, and RB hypophosphorylation. B. Growth kinetics of the H1666 (G466VBRAF low kinase activity) NSCLC cell line following treatment with PD0325901 (1 100 nM) or control (untreated). An initial rise in cell counts was followed by decrease in the number of viable cells at later time points (day 4). C. Photomicrographs of untreated and MEK inhibitor-treated H1666 (G466VBRAF) and PC9 (delE746-A750EGFR) cells, following 72 hours of exposure. D. Soft agar colony formation assays in the presence of increasing concentrations of PD0325901 reveal inhibition of HCC364 (V600EBRAF), but not PC9 (delE746-A750EGFR), colony growth.